Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

593P - AI-powered analysis of nuclear morphology associated with prognosis in high-grade serous carcinoma

Date

10 Sep 2022

Session

Poster session 09

Topics

Pathology/Molecular Biology

Tumour Site

Ovarian Cancer

Presenters

Chad Michener

Citation

Annals of Oncology (2022) 33 (suppl_7): S235-S282. 10.1016/annonc/annonc1054

Authors

C.M. Michener1, C. Kirkup2, B. Rahsepar2, J.S. Iyer2, J. Abel2, K. Leidal3, A. Khosla2, B. Trotter2, M. Lin2, M. Resnick4, B. Glass2, I. Wapinski2, F. Najdawi4

Author affiliations

  • 1 Gynecologic Oncology, Cleveland Clinic, 44195 - Cleveland/US
  • 2 Scientific Programs, PathAI, Inc., 02215 - Boston/US
  • 3 Machine Learning, PathAI, Inc., 02215 - Boston/US
  • 4 Pathology, PathAI, Inc., 02215 - Boston/US
More

Abstract 593P

Background

Ovarian carcinoma is a leading driver of cancer-related mortality in women, but predicting long-term survival at diagnosis remains a challenge. We demonstrate that AI-powered pathology can classify cells and tissue regions in the high-grade serous carcinoma (HGSC) tumor microenvironment, and reveal nuclear morphology (NM) associated with patient outcomes, directly from digitized hematoxylin and eosin (H&E)-stained whole slide images (WSI).

Methods

Machine learning (ML) models were trained using H&E WSI of ovarian carcinoma samples from both publicly available (e.g. TCGA) and proprietary sources (Total N=352 slides from 257 subjects). ML models were trained to label tissue regions (cancer epithelium, stroma, necrosis) and cell types (cancer epithelial cells, fibroblasts, and inflammatory cells) using 138,632 pathologist-provided annotations. A separate nuclear segmentation model was deployed on H&E WSI from 93 subjects to characterize NM at single-pixel resolution. Survival and clinically relevant statuses were regressed vs. nuclear features using univariate Cox or logistic regressions. False discovery rate correction was applied.

Results

ML-based predictions of tissue and cell classes showed concordance with manual pathologist consensus labels. Analysis of NM revealed that greater inter-nuclear variation in staining intensity and minor axis length were associated with reduced overall survival, reflecting the effect of variability in chromatin characteristics (corrected p=0.023, Hazard Ratio (HR) = 2.51) and inter-nuclear heterogeneity in shape and size across a slide (corrected p=0.035, HR=2.11), respectively. Greater variation in nucleus minor axis length was also correlated with increased number of aneuploidy events involving gains in chromosome arms (Spearman correlation r=0.41, p<0.001), in turn predicting reduced overall survival (corrected p=0.04, HR=2.12).

Conclusions

This analysis reveals a relationship between cancer cell nuclear morphological diversity, aneuploidy, and patient prognosis. Digital pathology can therefore identify objective, quantitative biomarkers that may help pathologists better stratify patients at diagnosis, allowing clinicians to avoid potentially toxic therapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

PathAI, Inc.

Funding

PathAI, Inc.

Disclosure

C.M. Michener: Financial Interests, Personal, Stocks/Shares: MedaSync. C. Kirkup: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. B. Rahsepar: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. J.S. Iyer: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. J. Abel: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. K. Leidal: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. A. Khosla: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. B. Trotter: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. M. Lin: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. M. Resnick: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. B. Glass: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. I. Wapinski: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc. F. Najdawi: Financial Interests, Institutional, Full or part-time Employment: PathAI, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.